natera.com

What It Is

Natera (natera.com) is a leading global cell-free DNA (cfDNA) liquid biopsy company headquartered in the United States. It focuses on non-invasive molecular diagnostic testing across three fields: oncology, women's reproductive health, and organ transplantation. It operates CAP/CLIA-accredited testing labs that meet international standards, has completed more than 16 million tests to date, and its technology is validated by over 400 peer-reviewed publications, earning high clinical recognition.

Core Offerings & Pricing

Natera's core products fall into three main categories:

• Oncology: Signatera MRD minimal residual disease testing, Altera comprehensive tumor sequencing, and Empower hereditary cancer screening
• Women's health: Fetal genetic disorder risk screening
• Organ health: Prospera non-invasive rejection risk testing for kidney, heart, and lung transplants

For pricing, most of Natera's core testing services are covered by U.S. Medicare and most private insurance plans. Eligible patients can have the majority of costs covered by insurance. For uninsured patients or those who do not meet coverage criteria, the platform offers self-pay pricing, and also provides financial assistance for qualifying low-income patients to eliminate cost as a barrier to testing.

Pros & Cons Analysis

Pros:
Natera has extensive technical expertise, and its testing performance is validated by large-scale clinical studies. The sensitivity and specificity of many core tests outperform traditional testing methods: for example, Prospera kidney transplant rejection testing reduces the missed diagnosis rate by roughly 3-fold compared to conventional serum creatinine testing. Testing only requires a blood draw, making it completely non-invasive and far more comfortable for patients than invasive biopsies.

Cons:
The company's core market is entirely focused on the U.S., and testing services are only available in the U.S. and a small number of other regions — Chinese users cannot directly apply for testing. The official website does not disclose specific self-pay pricing, leading to a lack of price transparency. It also only offers English-language service, with no Chinese interface support.

Eligible Users & Access From China

This service is primarily intended for U.S. clinical medical institutions, cancer patients, organ transplant recipients, and families planning pregnancy. Chinese users can access the official website directly without a VPN, but can only view publicly available information and cannot directly apply for testing services.